A retrospective analysis for patients with HER2-positive gastric cancer who were treated with trastuzumab-based chemotherapy: In the perspectives of ethnicity and histology

Jun Ho Yi, Jung Hun Kang, In Gyu Hwang, Hee Kyung Ahn, Hyun Jin Baek, Soon Il Lee, Do Hyoung Lim, Young Woong Won, Jun Ho Ji, Hyo Song Kim, Sun Young Rha, Sung Yong Oh, Kyung Eun Lee, Taekyu Lim, Chi Hoon Maeng, Moon Jin Kim, Seung Tae Kim, Jeeyun Lee, Joon Oh Park, Young Suk ParkHo Yeong Lim, Won Ki Kang, Se Hoon Park

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy. Materials and Methods Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chemotherapy were analyzed retrospectively. Results A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85 years) and the male:female ratio was 118 (70.2%):50 (29.8%). Fourteen (8.3%), 63 (37.5%), 75 (44.6%), and 11 (6.5%) patients had well, moderately, poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and 73 partial responses, the response rate was 50.6%. The median progression-free survival (PFS) was 10.2 months (95% confidence interval [CI], 8.7 to 11.7), and the median OS was 18.5 months (95% CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma) on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6 months vs. 19.0 months, p=0.025). Conclusion While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy may not be beneficial for Asians and patients with PDH, our data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer.

Original languageEnglish
Pages (from-to)553-560
Number of pages8
JournalCancer Research and Treatment
Volume48
Issue number2
DOIs
Publication statusPublished - 2016 Apr 1

Fingerprint

Stomach Neoplasms
Histology
Drug Therapy
Signet Ring Cell Carcinoma
Disease-Free Survival
Survival
Adenocarcinoma
Trastuzumab
Confidence Intervals
Safety

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Yi, Jun Ho ; Kang, Jung Hun ; Hwang, In Gyu ; Ahn, Hee Kyung ; Baek, Hyun Jin ; Lee, Soon Il ; Lim, Do Hyoung ; Won, Young Woong ; Ji, Jun Ho ; Kim, Hyo Song ; Rha, Sun Young ; Oh, Sung Yong ; Lee, Kyung Eun ; Lim, Taekyu ; Maeng, Chi Hoon ; Kim, Moon Jin ; Kim, Seung Tae ; Lee, Jeeyun ; Park, Joon Oh ; Park, Young Suk ; Lim, Ho Yeong ; Kang, Won Ki ; Park, Se Hoon. / A retrospective analysis for patients with HER2-positive gastric cancer who were treated with trastuzumab-based chemotherapy : In the perspectives of ethnicity and histology. In: Cancer Research and Treatment. 2016 ; Vol. 48, No. 2. pp. 553-560.
@article{30feb96b4c554aada19fa4b3abfcf91f,
title = "A retrospective analysis for patients with HER2-positive gastric cancer who were treated with trastuzumab-based chemotherapy: In the perspectives of ethnicity and histology",
abstract = "Purpose While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy. Materials and Methods Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chemotherapy were analyzed retrospectively. Results A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85 years) and the male:female ratio was 118 (70.2{\%}):50 (29.8{\%}). Fourteen (8.3{\%}), 63 (37.5{\%}), 75 (44.6{\%}), and 11 (6.5{\%}) patients had well, moderately, poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and 73 partial responses, the response rate was 50.6{\%}. The median progression-free survival (PFS) was 10.2 months (95{\%} confidence interval [CI], 8.7 to 11.7), and the median OS was 18.5 months (95{\%} CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma) on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6 months vs. 19.0 months, p=0.025). Conclusion While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy may not be beneficial for Asians and patients with PDH, our data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer.",
author = "Yi, {Jun Ho} and Kang, {Jung Hun} and Hwang, {In Gyu} and Ahn, {Hee Kyung} and Baek, {Hyun Jin} and Lee, {Soon Il} and Lim, {Do Hyoung} and Won, {Young Woong} and Ji, {Jun Ho} and Kim, {Hyo Song} and Rha, {Sun Young} and Oh, {Sung Yong} and Lee, {Kyung Eun} and Taekyu Lim and Maeng, {Chi Hoon} and Kim, {Moon Jin} and Kim, {Seung Tae} and Jeeyun Lee and Park, {Joon Oh} and Park, {Young Suk} and Lim, {Ho Yeong} and Kang, {Won Ki} and Park, {Se Hoon}",
year = "2016",
month = "4",
day = "1",
doi = "10.4143/crt.2015.155",
language = "English",
volume = "48",
pages = "553--560",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Cancer Association",
number = "2",

}

Yi, JH, Kang, JH, Hwang, IG, Ahn, HK, Baek, HJ, Lee, SI, Lim, DH, Won, YW, Ji, JH, Kim, HS, Rha, SY, Oh, SY, Lee, KE, Lim, T, Maeng, CH, Kim, MJ, Kim, ST, Lee, J, Park, JO, Park, YS, Lim, HY, Kang, WK & Park, SH 2016, 'A retrospective analysis for patients with HER2-positive gastric cancer who were treated with trastuzumab-based chemotherapy: In the perspectives of ethnicity and histology', Cancer Research and Treatment, vol. 48, no. 2, pp. 553-560. https://doi.org/10.4143/crt.2015.155

A retrospective analysis for patients with HER2-positive gastric cancer who were treated with trastuzumab-based chemotherapy : In the perspectives of ethnicity and histology. / Yi, Jun Ho; Kang, Jung Hun; Hwang, In Gyu; Ahn, Hee Kyung; Baek, Hyun Jin; Lee, Soon Il; Lim, Do Hyoung; Won, Young Woong; Ji, Jun Ho; Kim, Hyo Song; Rha, Sun Young; Oh, Sung Yong; Lee, Kyung Eun; Lim, Taekyu; Maeng, Chi Hoon; Kim, Moon Jin; Kim, Seung Tae; Lee, Jeeyun; Park, Joon Oh; Park, Young Suk; Lim, Ho Yeong; Kang, Won Ki; Park, Se Hoon.

In: Cancer Research and Treatment, Vol. 48, No. 2, 01.04.2016, p. 553-560.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A retrospective analysis for patients with HER2-positive gastric cancer who were treated with trastuzumab-based chemotherapy

T2 - In the perspectives of ethnicity and histology

AU - Yi, Jun Ho

AU - Kang, Jung Hun

AU - Hwang, In Gyu

AU - Ahn, Hee Kyung

AU - Baek, Hyun Jin

AU - Lee, Soon Il

AU - Lim, Do Hyoung

AU - Won, Young Woong

AU - Ji, Jun Ho

AU - Kim, Hyo Song

AU - Rha, Sun Young

AU - Oh, Sung Yong

AU - Lee, Kyung Eun

AU - Lim, Taekyu

AU - Maeng, Chi Hoon

AU - Kim, Moon Jin

AU - Kim, Seung Tae

AU - Lee, Jeeyun

AU - Park, Joon Oh

AU - Park, Young Suk

AU - Lim, Ho Yeong

AU - Kang, Won Ki

AU - Park, Se Hoon

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Purpose While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy. Materials and Methods Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chemotherapy were analyzed retrospectively. Results A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85 years) and the male:female ratio was 118 (70.2%):50 (29.8%). Fourteen (8.3%), 63 (37.5%), 75 (44.6%), and 11 (6.5%) patients had well, moderately, poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and 73 partial responses, the response rate was 50.6%. The median progression-free survival (PFS) was 10.2 months (95% confidence interval [CI], 8.7 to 11.7), and the median OS was 18.5 months (95% CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma) on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6 months vs. 19.0 months, p=0.025). Conclusion While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy may not be beneficial for Asians and patients with PDH, our data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer.

AB - Purpose While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy. Materials and Methods Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chemotherapy were analyzed retrospectively. Results A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85 years) and the male:female ratio was 118 (70.2%):50 (29.8%). Fourteen (8.3%), 63 (37.5%), 75 (44.6%), and 11 (6.5%) patients had well, moderately, poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and 73 partial responses, the response rate was 50.6%. The median progression-free survival (PFS) was 10.2 months (95% confidence interval [CI], 8.7 to 11.7), and the median OS was 18.5 months (95% CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma) on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6 months vs. 19.0 months, p=0.025). Conclusion While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy may not be beneficial for Asians and patients with PDH, our data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=84963894352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963894352&partnerID=8YFLogxK

U2 - 10.4143/crt.2015.155

DO - 10.4143/crt.2015.155

M3 - Article

C2 - 26323641

AN - SCOPUS:84963894352

VL - 48

SP - 553

EP - 560

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 2

ER -